MoonLake ImmunotherapeuticsMLTX

時価総額

$9億

PER

免疫療法開発の新興企業。IL-17A/IL-17F阻害を狙う候補薬SLKの臨床開発を展開。2022年4月のSPAC合併と2022年4月6日のナスダック上場、2023年6月30日の公開増資で約4.37億ドルの調達。スイス本社、英国・ポルトガル・ベルギーに拠点、2026年初頭の米国展開予定。

概要財務

サマリーテーブルに戻る

	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-	-	-64,506,051	-44,079,117	-121
Depreciation and amortization	-	-	-	-	1
Share-based compensation expense	-	-	10	7	7
Pension Expense (Reversal of Expense), Noncash	-	-	304,031	-85,254	1,300
Other non-cash items	-	-	-68,454	-484,762	227,012
Other receivables	-	-	68,355	839,733	2
Operating lease right-of-use assets	-	-	-	65,513	5,445
Prepaid expenses	283,057	-156,141	3	6	13
Trade and other payables	-	-	-1,314,318	2	7
Operating lease liabilities	-	-	-	-222,259	-1,423,163
Accrued expenses and other current liabilities	-	-	3	-326,725	5
Net cash flow used in operating activities	-316,692	-611,071	-55,893,900	-42,778,167	-116,587,263
Purchase of short-term marketable debt securities	-	-	42	176	350
Proceeds from maturities of short-term marketable debt securities	-	-	10	151	145
Purchase of property and equipment	-	-	16,009	284,634	519,520
Net cash flow used in investing activities	-115,000,000	-	-32,340,593	-25,184,324	-205,595,299
Proceeds from Issuance Initial Public Offering	-	-	-	482	53
Stamp duty on capital injection from MoonLake to MoonLake AG	-	-	-	3	1
Proceeds from Stock Options Exercised	-	-	-	-	242,004
Proceeds from Business Combination	-	-	135	-	-
Contribution for par value of Class V Shares	-	-	42,935	-	-
Repayment of loan liability	-	-	15	-	-
Buyback of unvested MoonLake AG Common Shares by MoonLake AG following an employee contract termination	-	-	-	-	50
Net cash flow provided by financing activities	117	-58,063	120	480	51
Effect of movements in exchange rates on cash held	-	-	8,540	-75,307	127,966
Net change in cash and cash equivalents	-	-	31	412	-270,742,888
Income Taxes Paid, Net	-	-	4,312	41,713	147,294
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	-	-	435,005	4	554,857